Skip to main content

Biosite and Oxford Partner on Colorectal Cancer Biomarker Study

NEW YORK, April 4 (GenomeWeb News) - Biosite and Oxford Genome Sciences today said they will co-evaluate protein-based disease markers for colorectal cancer.

 

Under the terms of the collaboration, Oxford will identify at least 25 proteins from blood and tissue samples from relapsing colorectal cancer patients, and Biosite will have the rights to develop blood-based diagnostic tests using one or more of the biomarkers.

 

Financial terms of the agreement were not disclosed.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.